Q-omics provides the consensus-scored MLANA profile across patient tissues and cancer cell-line models. MLANA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MLANA is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MLANA RNA expression shows 18,946 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SCLC, KIRC, and DLBC as cancer lineages where MLANA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MLANA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MLANA survival associations across molecular data types. MLANA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MLANA RNA expression–survival associations across cancer types. High MLANA expression shows unfavorable associations in CESC and LGG, but favorable associations in SCLC, READ, KIRC and PAAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for MLANA RNA expression.
This table summarizes MLANA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MLANA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MLANA shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in LIHC, CHOL and PRAD. The KIRC box plot shows higher MLANA RNA expression in normal versus tumor tissue (log2 FC = −0.275, t-test p < 0.001).
This table shows molecular features associated with MLANA in patient tissues and cancer cell lines. In patient samples, MLANA shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, MLANA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
